FDA approval brings biopharma firm one step closer to lucrative pharmaceutical submarket
Shares of Catalyst Pharmaceuticals (Nasdaq: CPRX) jumped more than 12 percent Friday following announcement of the U.S. Food and Drug Administration's stamp of approval on its latest drug.
A medicine created by the Coral Gables-based company called Firdapse earned “orphan” status, a designation for drugs that safely and effectively treat or prevent rare diseases.
Firdapse aims to treat a portion of the 100,000 Americans who suffer of myasthenia gravis, a degenerative neuromuscu lar disease that…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Debora Lima Source Type: news
More News: Food and Drug Administration (FDA) | Health | Health Management | Myasthenia Gravis | Neurology | Pharmaceuticals | Rare Diseases